Literature DB >> 21401982

Novel treatments for type 2 diabetes.

Jason Seewoodhary, Stephen C Bain.   

Abstract

Entities:  

Mesh：

Year:  2011        PMID： 21401982      PMCID： PMC3020044          DOI： 10.3399/bjgp11X548884

Source DB:  PubMed          Journal:  Br J Gen Pract        ISSN： 0960-1643            Impact factor:   5.386


× No keyword cloud information.
  12 in total

Review 1.  SGLT2 inhibition--a novel strategy for diabetes treatment.

Authors:  Edward C Chao; Robert R Henry
Journal:  Nat Rev Drug Discov       Date:  2010-05-28       Impact factor: 84.694

2.  Exenatide-associated ischemic renal failure.

Authors:  Wolfgang J Weise; Mala S Sivanandy; Clay A Block; Richard J Comi
Journal:  Diabetes Care       Date:  2009-02       Impact factor: 19.112

3.  Exenatide and pancreatitis: an update.

Authors:  Steve C Bain; Jeffrey W Stephens
Journal:  Expert Opin Drug Saf       Date:  2008-11       Impact factor: 4.250

4.  Inhibition of fructose 1,6-bisphosphatase reduces excessive endogenous glucose production and attenuates hyperglycemia in Zucker diabetic fatty rats.

Authors:  Paul D van Poelje; Scott C Potter; Visvanathan C Chandramouli; Bernard R Landau; Qun Dang; Mark D Erion
Journal:  Diabetes       Date:  2006-06       Impact factor: 9.461

5.  Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study.

Authors:  Robert R Henry; A Michael Lincoff; Sunder Mudaliar; Michael Rabbia; Cathy Chognot; Matthias Herz
Journal:  Lancet       Date:  2009-06-08       Impact factor: 79.321

6.  Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes.

Authors:  J Michael Gaziano; Anthony H Cincotta; Christopher M O'Connor; Michael Ezrokhi; Dean Rutty; Z J Ma; Richard E Scranton
Journal:  Diabetes Care       Date:  2010-03-23       Impact factor: 17.152

7.  Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes.

Authors:  Sharon H Saydah; Judith Fradkin; Catherine C Cowie
Journal:  JAMA       Date:  2004-01-21       Impact factor: 56.272

Review 8.  Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.

Authors:  Nasser Mikhail
Journal:  Expert Opin Investig Drugs       Date:  2008-06       Impact factor: 6.206

9.  Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years.

Authors:  David C Klonoff; John B Buse; Loretta L Nielsen; Xuesong Guan; Christopher L Bowlus; John H Holcombe; Matthew E Wintle; David G Maggs
Journal:  Curr Med Res Opin       Date:  2008-01       Impact factor: 2.580

10.  Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes - a review.

Authors:  Katrine B Hansen; Tina Vilsbøll; Filip K Knop
Journal:  Diabetes Metab Syndr Obes       Date:  2010-05-17       Impact factor: 3.168
View more
  1 in total

1.  Novel treatments for type 2 diabetes.

Authors:  Alan Searle
Journal:  Br J Gen Pract       Date:  2011-05       Impact factor: 5.386
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.